Adjuvant chemotherapy for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative primary breast cancer, which accounts for approximately 70% of cases [3], is useful for reducing the risk of recurrence and improving survival prognosis. Here, NR4A1 is linked to breast carcinoma.